Page 88 - Michael Erman News Today

HEALTH-CORONAVIRUS/ASTRAZENECA-USA (EXCLUSIVE, UPDATE 1):EXCLUSIVE-U.S. authorization of AstraZeneca vaccine could come in April, independent monitors assessing data...

<div class="at-above-post addthis_tool" data-url="https://www.metro.us/biden-prepares-for-challenges/"></div>WASHINGTON (Reuters) – President Joe Biden on Wednesday directed his administration to procure 100 million more doses of the single-shot Johnson & Johnson coronavirus vaccine to boost U.S. supply in the event of “unexpected challenges” in the pandemic. The White House order comes as it seeks to speed up the process of inoculating peopl...

The European Union's drugs regulator on Thursday recommended conditionally approving Johnson & Johnson's single dose COVID-19 vaccine, following authorizations in the United States and Canada.

Pfizer Inc and BioNTech SE said on Thursday that real-world data from Israel suggests their COVID-19 vaccine is 94% effective in preventing asymptomatic infections, meaning it could significantly reduce transmission.

Pfizer Inc and BioNTech SE said on Thursday that real-world data from Israel suggests their COVID-19 vaccine is 94% effective in preventing asymptomatic infections, meaning it could significantly reduce transmission.

Pfizer Inc and German partner BioNTech SE will exceed their original global production target for COVID-19 vaccines by as much as 20% this year, as they ramp up production a year into the global pandemic, Pfizer Chief Executive Albert Bourla said on Thursday.

(Adds details, background) By Michael Erman and Maayan Lubell NEW YORK/JERUSALEM, March 11 (Reuters) - Pfizer Inc and BioNTech SE said on Wednesday th...

The European Union's drugs regulator on Thursday recommended conditionally approving Johnson & Johnson's single dose COVID-19 vaccine, following authorizations in the United States and Canada.

Read more about Eli Lillys combo therapy for Covid-19 gets good results on Business Standard. Eli Lilly & Co.s combination antibody therapy reduced the risk of hospitalization or death by 87% in high-risk patients with newly-diagnosed Covid-19, the company said

Biden is likely to highlight the issue at a meeting with the chief executives of J&J and Merck & Co later on Wednesday. Merck has agreed to partner with J&J to produce its vaccine.